XML 20 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 6 Months Ended
Dec. 31, 2013
Dec. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (11,460) $ (8,485)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 937 276
Loss on sale of property equipment 4   
Impairment of property and equipment 31   
Stock-based compensation to employees, directors and non-employee consultants 2,336 1,684
Stock compensation to investor relations consultants    278
Increase in other accounts receivable (401) (808)
Increase (decrease) in prepaid expenses 116 (577)
Decrease in trade payables 488 2,179
Increase in other accounts payable and accrued expenses (167) (48)
Decrease in deferred revenues (190) (389)
Decrease in advance payment from United Therapeutics (96) (977)
Linkage differences and Increase (decrease) interest on short and long-term deposit and restricted lease deposit 1 (102)
Accretion of discount, amortization of premium and changes in accrued interest from marketable securities 465 53
Loss (gain) from sale of investments of available for sale marketable securities (164) 23
Accrued severance pay, net (7) 3
Net cash used in operating activities (8,107) (6,890)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of property and equipment (1,169) (3,338)
Repayment of (Investment in) short-term deposits 7,961 (10,646)
Repayment of long-term deposits (3) 521
Repayment of long-term restricted deposit 116 9
Proceeds from sale of available-for-sale marketable securities 2,963 459
Proceeds from redemption of available-for-sale marketable securities 583 304
Investment in available-for-sale marketable securities (7,904) (2,204)
Net cash provided by (used in) investing activities 2,547 (14,895)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Issuance of common stock and warrants, net of issuance costs    34,106
Exercise of options and warrants 1,179 1,838
Net cash provided by financing activities 1,179 35,944
Increase (decrease) in cash and cash equivalents (4,381) 14,159
Cash and cash equivalents at the beginning of the period 9,007 9,389
Cash and cash equivalents at the end of the period 4,626 23,548
Supplemental disclosure of cash flow activities:    
Cash paid during the period for taxes due to non-deductible expenses 35 3
Supplemental disclosure of non-cash activities:    
Purchase of property and equipment on credit 258 588
Issuance of common stock under CHA agreement 10,414   
Stock based compensation to contractor    $ 1,400